Results 31 to 40 of about 23,498 (195)

Natalizumab in cerebrospinal fluid and breastmilk of patients with multiple sclerosis

Therapeutic Advances in Neurological Disorders, 2023
Background: Natalizumab is a highly effective monoclonal antibody for the treatment of multiple sclerosis (MS), which can diffuse in different anatomical compartments, including cerebrospinal fluid (CSF) and milk.
Ilaria Callegari, Mika Schneider, Vera Aebischer, Margarete M. Voortman, Undine Proschmann, Tjalf Ziemssen, Raija Lindberg, Bettina Fischer-Barnicol, Michael Khalil, Ludwig Kappos, Jens Kuhle, Nicholas S.R. Sanderson, Tobias Derfuss   +12 more
doaj   +1 more source

Peripheral blood biomarkers in multiple sclerosis. [PDF]

, 2015
Multiple sclerosis is the most common autoimmune disorder affecting the central nervous system. The heteroge-neity of pathophysiological processes in MS contributes to the highly variable course of the disease and unpre-dictable response to therapies ...
Acheson, Achiron, Ada Francia, Agmon-Levin, Aktas, Alatab, Alexander, Amorini, Anderson, Antonella D'Ambrosio, Arbour, Arnson, Arrambide, Ascherio, Ascherio, Ascherio, Axtell, Bar-Or, Barkhof, Barkhof, Barteneva, Bartosik-Psujek, Berger, Bertolotto, Bertolotto, Bertolotto, Bianco, Bielekova, Biomarkers Definitions Working Group, Bittner, Bloomgren, Braun, Brettschneider, Brex, Browne, Burger, Bustamante, Bustamante, Buttmann, Buzas, Bălaşa, Cantorna, Carotenuto, Carson, Cermelli, Chabas, Chen, Ciusani, Clifford, Cocucci, Colombo, Comabella, Comabella, Comabella, Comabella, Comi, Confavreux, Correale, Corvol, Cox, Creeke, D'Aurizio, D'Souza, Dalmau, De Jager, De Jager, De Santis, Deisenhammer, Derfuss, Dhib-Jalbut, Distler, Doyle, Du, Egg, Ehling, Eikelenboom, Engelhardt, Esteller, Eulalio, Fabriek, Farrell, Fenoglio, Fialová, Fissolo, Fonalledas Perelló, Fox, Freedman, Friedman, Galboiz, Gandhi, Gao, Ge, Gianchecchi, Gilli, Gilli, Giovannoni, Goldberg, Goodin, Graber, Graber, Gresle, Gresle, Guo, Haak, Haller, Hanke, Harris, Hartung, Hayes, Hecker, Hecker, Hellerqvist, Hinson, Horstman, Huang, Huang, Hur, Inoue, Ioannidis, Jimenez, Johnson, Julien, Junker, Kacperska, Kallaur, Kamath, Kasper, Kayagaki, Keller, Kemppinen, Knox, Korn, Korteweg, Kuenz, Kuhle, Kurtzke, Kvistad, Kwon, Lai, Lalive, Laroni, Lassmann, Lassmann, Lau, Lemire, Leppert, Leray, Lewis, Liang, Lily, Lin, Lindberg, Linington, Liotta, Littman, Liu, Lolli, Lopatinskaya, Lopatinskaya, Losseff, Losseff, Losy, Lovett-Racke, Lowery-Nordberg, Lublin, Lublin, Lucchinetti, Lycke, Lünemann, Lünemann, Major, Malucchi, Marchi, Markiewicz, Markovic-Plese, Martinelli-Boneschi, Marzesco, Masuoka, Mayer, Mazzali, McDonald, Miller, Minagar, Minagar, Minagar, Minagar, Missler, Mitchell, Momen-Heravi, Morel, Moreno, Mowry, Munger, Muralidharan-Chari, Murugaiyan, Myers, Nelissen, Nelissen, Norling, O'Connell, O'Connell, Oliveira, Oliver, Opdenakker, Opsahl, Otaegui, Pachner, Pachner, Pachner, Paola Margutti, Papini, Park, Pawate, Pelajo, Pender, Petereit, Peterson, Petrocca, Poloni, Probstel, Qin, Qu, Quintana, Redell, Reder, Reindl, Reindl, Rieckmann, Rieder, Riverol, Romo-Tena, Rovaris, Rudick, Rudick, Rudick, Sadiq, Salama, Sato, Schwarz, Schwarz, Selmi, Semra, Sendid, Sharief, Sharief, Sharief, Sharief, Shaw, Sheremata, Sievers, Silber, Silvia Zamboni, Siman, Simona Pontecorvo, Simpson, Soldan, Soldan, Sospedra, Srivastava, Stewart, Stüve, Sundström, Sáenz-Cuesta, Sáenz-Cuesta, Tania Colasanti, Tao, Teunissen, Tintoré, Trabattoni, Trampe, Turiák, van Horssen, Varga, Vartanian, Verderio, Villoslada, Virtanen, Vogt, Vogt, Wandinger, Wang, Waschbisch, Waubant, Waubant, Waubant, Waubant, Weinstock-Guttman, Wekerle, Xiao, Yong, Yong, Yousry, Zahednasab, Zang, Zhang, Zhu, Zipp, Zisimopoulou, Zula   +298 more
core   +1 more source

The role of natalizumab in the treatment of multiple sclerosis: benefits and risks

Therapeutic Advances in Neurological Disorders, 2017
Natalizumab, a monoclonal antibody that blocks lymphocyte infiltration in the central nervous system, is a valuable tool in the treatment of relapsing forms of multiple sclerosis (MS). In a phase III clinical trial comparing natalizumab with placebo over
Barry A. Singer
doaj   +1 more source

Self-Limited Cytomegalovirus Infection During Natalizumab Treatment for Multiple Sclerosis

European Journal of Case Reports in Internal Medicine, 2019
Natalizumab is indicated as monotherapy for the treatment of relapsing-remitting multiple sclerosis; it prevents outbreaks and delays the progression of physical disability.
Marina Rodrigues Lima, Luis Arthur Brasil Gadelha Farias, Maycon Fellipe da Ponte, Luís Edmundo Teixeira de Arruda Furtado   +3 more
doaj   +1 more source

Natalizumab for relapsing-remitting multiple sclerosis

Neurología (English Edition), 2011
Introduction: Natalizumab is a monoclonal antibody that inhibits leukocyte migration across the blood-brain barrier and has been approved for the treatment of relapsing-remitting multiple sclerosis.
A. Horga, M. Tintoré
doaj   +1 more source

Erythrocytes in multiple sclerosis: forgotten contributors to the pathophysiology? [PDF]

, 2016
Multiple sclerosis (MS) is an autoimmune disease characterised by lymphocytic infiltration of the central nervous system and subsequent destruction of myelin and axons. On the background of a genetic predisposition to autoimmunity, environmental triggers
Groen, Kira, Lechner-Scott, Jeannette, Maltby, Vicki E., Sanders, Katherine, Scott, Rodney J., Tajouri, Lotti   +5 more
core   +2 more sources

Inflammatory Activity on Natalizumab Predicts Short-term but not Long-term Disability in Multiple Sclerosis [PDF]

, 2017
BACKGROUND: In people with multiple sclerosis treated with interferon-beta or glatiramer acetate, new MRI lesions and relapses during the first year of treatment predict a poor prognosis.
Dahdaleh, S, Gafson, AR, Jones, B, Malik, O, Nicholas, R, Raffel, J   +5 more
core   +1 more source

Budget impact analysis of natalizumab biosimilar on pharmaceutical expenditure for the treatment of relapsing-remitting multiple sclerosis in Italy

AboutOpen
Background: The availability of high-efficacy disease-modifying therapy (DMT), including natalizumab, improved treatment efficacy in adults with highly-active relapsing-remitting multiple sclerosis (RRMS).
Roberto Bergamaschi, Marco Capobianco , Roberto Ravasio   +2 more
doaj   +1 more source

Multiple Sclerosis Treatment with Natalizumab: Analysis of a Hospital-Based Cohort

Acta Médica Portuguesa, 2014
Introduction: Natalizumab is licensed as monotherapy for relapsing–remitting multiple sclerosis. Since pivotal studies showing natalizumab efficacy, several subsequent studies confirmed the reduction in annualized relapse rate and the slowing of ...
Ana Teresa Carvalho, Pedro Abreu, Maria José Sá   +2 more
doaj   +1 more source

The effect of natalizumab on disability score and relapse rate of multiple sclerosis patients: a prospective cohort study

Clinical and Translational Medicine, 2018
Multiple sclerosis (MS) is a progressive immune-related disorder of the central nervous system leading to destruction of myelin sheaths. Natalizumab is a humanized monoclonal antibody against the cell adhesion molecule α4-integrin which has been approved
Mehrdokht Mazdeh, Shno Hosseini, Mohammad Taheri, Soudeh Ghafouri-Fard   +3 more
doaj   +1 more source